Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 5/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885986 | 1.00 | NR1H3 (0.34) | NR1H3NR1H2KMT2AMEN1NPC1 | |
| SCHEMBL6359890 | 0.90 | NR1H3 (0.33) | NR1H3KMT2AMEN1NPC1RAB9A | |
| SCHEMBL5804197 | 0.85 | TBXAS1 (0.38) | NR1H3NR1H2KMT2AMEN1NPC1 | |
| SCHEMBL5804198 | 0.85 | TBXAS1 (0.38) | NR1H3NR1H2KMT2AMEN1NPC1 | |
| SCHEMBL29451601 | 0.79 | SMN1; SMN2 (0.38) | NR1H3NR1H2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4575361 | 0.75 | FBP1 (0.44) | NR1H3NR1H2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4575360 | 0.75 | FBP1 (0.44) | NR1H3NR1H2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3885465 | 0.74 | CASP3 (0.45) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6364141 | 0.74 | ALDH1A1 (0.43) | KMT2ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29451792 | 0.74 | HSD17B10 (0.41) | NR1H3KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| EP-1149063-B1 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1149063-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-10-31 | — | — | EP | disclosed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | disclosed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | PPARG, PPARA, PPARD | NR1H3 4/4885NR1H2 5/4885KMT2A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.